Jisanda/Bingtonsha original drug manufacturers and generic drug information

Epclusa was originally developed by Gilead in the United States. It is the first single-tablet anti-hepatitis C drug combination approved by the FDA and suitable for all six HCV genotypes. Its pharmacological basis is two direct-acting antiviral drugs (DAAs): sofosbuvir inhibits NS5B polymerase, and velpatasvir blocks NS5A protein function, thereby preventing virus replication and infection process. With its excellent therapeutic broad spectrum and viral clearance rate of over 95%, Epclusa quickly gained a leading position in the international market and became one of the standard treatment options for chronic hepatitis C.

Due to the large global burden of hepatitis C, Gilead has implemented drug authorization and generic mechanisms in many developing countries. According to the patent pool licensing agreement, many pharmaceutical companies in India, Bangladesh, Laos and other countries have been legally authorized to produce and sell third-generation generic versions of Jilin to reduce drug costs and expand accessibility. Among them, sofosbuvir + velpatasvir generics produced by Indian companies such as MYLAN, Natco, and Hetero are the most common choices; Beacon Pharma of Bangladesh and Luscius Pharma of Laos have also launched corresponding generic versions. Although the price is much lower than the original drugs, these generic drugs must meet the World Health Organization (WHO) or Gilead authorization standards, and the drugs are basically the same in terms of dosage, specifications, efficacy and safety.

It should be noted that these generic drugs have not been officially approved for marketing by the Food and Drug Administration in mainland China, so they cannot be purchased directly in hospitals or pharmacies. Some patients may obtain these drugs from overseas, and they need to pay special attention to the authenticity and legality risks of the drugs when using them. The original drugEpclusa is currently on the market in China and has been included in the medical insurance system. It is recommended to give priority to formal channels to obtain drug treatment to ensure efficacy and safety.

Reference: https://www.epclusa.com/